Navigation Links
Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Date:1/12/2009

BETHESDA, Md., Jan. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced the signing of an option, collaboration and license agreement with Bayer Schering Pharma AG, Germany, under which Bayer Schering Pharma has the exclusive option to obtain a license to one of Micromet's preclinical BiTE antibodies against an undisclosed oncology target.

Under the terms of the agreement, Bayer Schering Pharma will pay Micromet a Euro 4.5 million fee (approx. US$ 6 million) to secure a one year option on a specific BiTE antibody. Bayer Schering Pharma may exercise this option prior to January 5, 2010 through the additional payment of an option exercise fee. The exercise of the option would trigger a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma would assume full control of the further development and commercialization of the BiTE antibody. Micromet would be eligible for an option exercise fee and milestone payments of up to Euro 290 million (approx. US$ 390 million) in total and up to double digit royalties based on tiered net sales of the product. In addition, Micromet would be reimbursed for its R&D expenses incurred in connection with the development of the BiTE antibody in the collaboration with Bayer Schering Pharma.

"We are very pleased with Bayer Schering Pharma's interest in this preclinical BiTE antibody program and their financial commitment to secure exclusive access for the next 12 months. This deal represents further validation of our BiTE antibody technology by a major oncology company," said Christian Itin, Micromet's
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development company committed ... announced that the United States Patent & Trademark Office ... month of August that are part of a standard ... patents are: , U.S.RE45,065 issued August ... and , U.S.RE45,095 issued August 26, 2014.  ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... For Women in Science program is welcoming the 15 International Fellows ... , On Wednesday, March 28, from 4 pm to ... the Pasteur Institute in Paris. Following these presentations, a cocktail ... be met individually , , On ...
... physics of massive particles has intrigued physicists for more than ... exhibit wave-like behaviour in conflict with our everyday ideas ... of scientists now succeeded in shooting a movie which shows ... molecules which is so large (up to 0.1 mm) that ...
... March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the ... announce that the company will be exhibiting at the ... College of Cardiology (ACC) in Chicago, March 24-27, Booth ... PREvent is the first and only multiple biomarker blood ...
Cached Biology Technology:The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2
(Date:9/2/2014)... milk is considered the most ideal source of ... a critical role in the evolution and civilizations ... milk contains a large number of bacterial species, ... comes as no surprise to scientists and physicians. ... considered to be the result of co-evolutionary and ...
(Date:9/2/2014)... between our immune systems and cholera bacteria, humans may ... phages. In a new study, researchers from Tufts University, ... Health Laboratory, and elsewhere, report that phages can force ... to survive. Importantly, the study published in ... phage predation occurs during human infection. , First author ...
(Date:9/2/2014)... the price of your integrity? Tell the truth; everyone has ... at some point, we,ll lie if the benefit is great ... in which we make that decision. , The result ... . , "We prefer to be honest, even if ... and a postdoctoral associate at the Virginia Tech Carilion ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4
... Medicine researchers played a key role in the largest ... 11 new regions of the genome that contribute to ... therapeutic targets to investigate. Published October 27 in ... of the genetic factors contributing to Alzheimer,s and expands ...
... A group of students and faculty at Grand Valley State ... new methods to further a growing medical field that aims ... group of four Grand Valley students and graduates, and Anthony ... the World Molecular Imaging Congress, one of the largest meetings ...
... Ore. -- (Oct. 25, 2013) -- Twenty grams of essential amino ... weeks after knee-replacement surgeries helped 16 patients, mean age 69, recover ... ingesting a placebo. The approach -- detailed in a paper ... the Journal of Clinical Investigation -- could spell relief ...
Cached Biology News:International collaboration finds 11 new Alzheimer's genes to target for drug discovery 2GVSU students contribute to growing medical field 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
...
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: